Business
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap
Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA
About this update from Yd Bio Limited
[{"type":"text","content":"Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of critical milestones across its core platforms: stem cell therapy & exosome platforms focused on ophthalmology conditions, early cancer detection powered by DNA methylation and next-generation precision diagnostics. The Company also outlined a focused, catalyst-driven strategy for 2026, and plans to transition from platform validation to accelerated asset-level clinical and commercial development, subject to regulatory feedback and resource availability. \"2025 has been a transformative year for YD Bio, as we've systematically de-risked our foundational platforms and strategically positioned ourselves for rapid advancement,\" said Dr. Ethan Shen, Chairman and CEO of the Company. The Company has completed key CMC activities and filed supporting DMFs intended to facilitate future submissions. The FDA has not approved any product. With these key activities the Company expects to enter a catalyst-rich period through 2027, driven by subsequent regulatory submissions and feedback, additional clinical initiations and their results, and strategic growth across our diverse portfolio which the success and timing remain uncertain. Accelerating Clinical Development Across Global Programs Cell Therapy and Exosome Platform: Manufacturing and Regulatory De-risking Completed YD Bio has achieved comprehensive Chemistry, Manufacturing, and Controls (CMC) development for its Limbal Stem Cell (LSC) platform and LSC-derived exosome products. This includes successful batch testing and qualification of primary LSC cell sources, establishment of scalable cell expansion and cryopreservation methods, and definition of cell specifications. Furthermore, robust exosome expansion, purification, and potency assay methods have been developed, alongside established exosome specifications. Relevant supporting Standard Operating Procedures (SOPs) are finalized, ensuring manufacturing readiness for Investigational New Drug (IND) applications. The Company plans to continue strengthening its regulatory foundation. The Company has filed Drug Master Files (DMFs) with the U.S. Food and Drug Administration...